DARPA awarded up to $11.312 million to UC San Diego to develop engineered red blood cells intended to temporarily improve oxygen delivery. Over three years, the project will test the concept of “smart” red blood cells that can boost performance and health metrics, with an initial focus on military personnel in harsh environments. The program sits at the intersection of blood cell engineering and translational physiology, aiming for a temporary performance benefit rather than a permanent therapeutic alteration. If successful, the platform could also extend to conditions where oxygen delivery to tissues is impaired, including certain cardiovascular and vascular diseases. For biotech R&D, the award signals defense-backed interest in next-generation blood therapeutics and may spur new work in RBC engineering and scalable manufacturing approaches.